Overview

Raised to Date: Raised: $1,008,951

Deal Terms

Investment Momentum

Company Profile

Deal Summary

Financials

Funding History

Growth Charts

Total Commitments ($USD)

Platform

Wefunder

Start Date

12/01/2021

Close Date

07/31/2022

Min. Goal

$50,000

Max. Goal

$1,070,000

Min. Investment

$100

Security Type

Convertible Note

Series

Pre-Seed

SEC Filing Type

RegCF    

Early Bird Val. Cap

$20,000,000

Valuation Cap

$25,000,000

Discount

20%

Rolling Commitments ($USD)

Status

Funded

Reporting Date

07/30/2022

Days Remaining

Funded

% of Min. Goal

Funded

% of Max. Goal

Funded

Likelihood of Max

Funded

Avg. Daily Raise

$4,187

# of Investors

386

Momentum

Funded

Create a free account today to gain access to KingsCrowd analytics.

Logos provided by Clearbit

Sen-Jam Pharmaceutical

Year Founded

2017

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2B

Margin

High

Capital Intensity

High

Location

Huntington, New York

Business Type

Growth

Company Website

Sen-Jam Pharmaceutical, with a valuation of $25 million, is raising funds on Wefunder. The pharmaceutical company makes highly accessible, safe, and affordable drugs that work. The drugs of Sen-Jam Pharmaceutical combine NSAIDs and antihistamines to prevent inflammation and associated pain. Sen-Jam Pharmaceutical is majorly targeting opioid withdrawal, alcohol hangover prevention, and COVID-19 therapeutic. Jim Iversen and Jackie Iversen founded Sen-Jam Pharmaceutical in August 2017. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $1,070,000. The campaign proceeds will be used for product development, regulatory affairs, marketing, communications, and intellectual property advancement.

Summary Profit and Loss Statement

	Most Recent Year	Prior Year
Revenue	$0	$0
COGS	$0	$0
Tax	$0	$860
Net Income	$-368,918	$-280,006

Summary Balance Sheet

	Most Recent Year	Prior Year
Cash	$12,240	$174
Accounts Receivable	$0	$0
Total Assets	$634,559	$670,364
Short-Term Debt	$22,039	$0
Long-Term Debt	$395,075	$0
Total Liabilities	$417,114	$0

Financials as of: 12/01/2021

Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name	Close Date	Platform	Valuation/Cap	Total Raised	Security Type	Status	Reg Type
Sen-Jam Pharmaceutical	04/28/2024	Wefunder	$80,000,000	$1,034,009	Convertible Note	Active	RegCF
Sen-Jam Pharmaceutical	01/05/2024	Self Managed	-	-	Convertible Note	Funded	RegD 506(c)
Sen-Jam Pharmaceutical	01/10/2023	StartEngine	$69,979,019	$312,093	Equity - Common	Funded	RegCF
Sen-Jam Pharmaceutical	07/30/2022	Wefunder	$25,000,000	$1,008,951	Convertible Note	Funded	RegCF

Create a free account today to gain access to KingsCrowd analytics.

• Price per Share
• Valuation
• Revenue
• Employees

Price per Share Valuation Revenue Employees

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Sen-Jam Pharmaceutical Founder Jim Iversen on Making Effective and Affordable Drugs

Prescription drug prices in the United States are painfully high. Americans pay more than twice as much as other countries for medication. This can weigh especially heavily on individuals without insurance who are struggling to make ends meet. 

In recognition of this problem, Sen-Jam Pharmaceutical aims to develop and sell affordable and effective oral anti-inflammation medicine. The company is working on eight products to address specific conditions, including COVID-19, opioid withdrawal, and hangovers. We reached out to co-founder and CEO Jim Iversen to learn more about the origins of the business and its plans following the raise.

Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.

Read Founder Interview